Chronic supplementation of proanthocyanidins reduces postprandial lipemia and liver miR-33a and miR-122 levels in a dose-dependent manner in healthy rats

Journal of Nutritional Biochemistry

Volumn 25, Issue 2, 2014, Pages 151-156

  Baselga Escudero, Laura ^a   Blade, Cinta ^a   Ribas Latre, Aleix ^a   Casanova, Ester ^a   Salvadó, M Josepa ^a   Arola, Lluis ^a   Arola Arnal, Anna ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Abca1; Cholesterol; Fas; Flavonoids; MicroRNAs; Triglycerides

Indexed keywords

CATECHIN; CHOLESTEROL; COUMARIC ACID; DIMER; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; FLAVANOL DERIVATIVE; GALLIC ACID; GRAPE SEED PROANTHOCYANIDIN EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPERIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MICRORNA 122; MICRORNA 33A; PROANTHOCYANIDIN; PROCYANIDIN; PROTOCATECHUIC ACID; PRUNIN; QUERCETIN; TETRAMER; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VANILLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; GENE EXPRESSION; GENE TARGETING; HYPERLIPIDEMIA; LIPID METABOLISM; LIPID STORAGE; LIVER WEIGHT; LONG TERM CARE; MALE; NONHUMAN; POSTPRANDIAL STATE; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ABCA1; CHOLESTEROL; FAS; FLAVONOIDS; MICRORNAS; TRIGLYCERIDES;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERLIPIDEMIAS; LIVER; MALE; MICRORNAS; POSTPRANDIAL PERIOD; PROANTHOCYANIDINS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84892538136     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2013.09.014     Document Type: Article

References (38)

1. Burton-Freeman B. Postprandial metabolic events and fruit-derived phenolics: a review of the science. Br J Nutr 2010, 104:S1-S14.
2. Patsch J.R., Miesenbock G., Hopferwieser T., Muhlberger V., Knapp E., Dunn J.K., et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992, 12:1336-1345.
3. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316.
4. Blade C., Arola L., Salvado M.J. Hypolipidemic effects of proanthocyanidins and their underlying biochemical and molecular mechanisms. Mol Nutr Food Res 2010, 54:37-59.
5. Montagut G., Bladé C., Blay M., Fernández-Larrea J., Pujadas G., Salvadó M.J., et al. Effects of a grape seed procyanidin extract (GSPE) on insulin resistance. J Nutr Biochem 2010, 21:961-967.
6. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
7. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
8. Breving K., Esquela-Kerscher A. The complexities of microRNA regulation: mirandering around the rules. Int J Biochem Cell Biol 2010, 42:1316-1329.
9. Friedman R.C., Farh K.K., Burge C.B., Bartel D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009, 19:92-105.
10. Rottiers V., Näär A.M. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012, 13:239-250.
11. Ramírez C.M., Goedeke L., Fernández-Hernando C. "Micromanaging" metabolic syndrome. Cell Cycle 2011, 10:3249-3252.
12. Fernandez-Hernando C., Ramirez C.M., Goedeke L., Suarez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013, 33:178-185.
13. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012, 122:2884-2897.
14. Hsu S., Wang B., Kota J., Yu J., Costinean S., Kutay H., et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 2012, 122:2871-2883.
15. Moore K.J., Rayner K.J., Suarez Y., Fernandez-Hernando C. The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr 2011, 31:49-63.
16. Elmén J., Lindow M., Schütz S., Lawrence M., Petri A., Obad S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
17. Esau C., Davis S., Murray S.F., Yu X.X., Pandey S.K., Pear M., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3:87-98.
18. Iliopoulos D., Drosatos K., Hiyama Y., Goldberg I.J., Zannis V.I. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010, 51:1513-1523.
19. Fernandez-Hernando C., Suarez Y., Rayner K.J., Moore K.J. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011, 22:86-92.
20. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. Nature 2010, 465:721-727.
21. Parra P., Serra F., Palou A. Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One 2010, 5:e13005.
22. Arola-Arnal A., Blade C. Proanthocyanidins modulate microRNA expression in human HepG2 cells. PLoS One 2011, 6:e25982.
23. Baselga-Escudero L., Blade C., Ribas-Latre A., Casanova E., Salvado M.J., Arola L., et al. Grape seed proanthocyanidins repress the hepatic lipid regulators miR-33 and miR-122 in rats. Mol Nutr Food Res 2012, 56:1636-1646.
24. Quesada H., Diaz S., Pajuelo D., Fernandez-Iglesias A., Garcia-Vallve S., Pujadas G., et al. The lipid-lowering effect of dietary proanthocyanidins in rats involves both chylomicron-rich and VLDL-rich fractions. Br J Nutr 2012, 108:208-217.
25. Del Bas J.M., Fernandez-Larrea J., Blay M., Ardevol A., Salvado M.J., Arola L., et al. Grape seed procyanidins improve atherosclerotic risk index and induce liver CYP7A1 and SHP expression in healthy rats. FASEB J 2005, 19:479-481.
26. Quiñones M., Guerrero L., Suarez M., Pons Z., Aleixandre A., Arola L., et al. Low-molecular procyanidin rich grape seed extract exerts antihypertensive effect in males spontaneously hypertensive rats. Food Res Int 2013, 51:587-595.
27. Alipour A., Elte J.W., van Zaanen H.C., Rietveld A.P., Castro Cabezas M. Novel aspects of postprandial lipemia in relation to atherosclerosis. Atheroscler Suppl 2008, 9:39-44.
28. Ursini F., Zamburlini A., Cazzolato G., Maiorino M., Bon G.B., Sevanian A. Postprandial plasma lipid hydroperoxides: a possible link between diet and atherosclerosis. Free Radic Biol Med 1998, 25:250-252.
29. van Oostrom A.J., van Wijk J., Cabezas M.C. Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis. Drugs 2004, 64:19-41.
30. Del Rio D., Rodriguez-Mateos A., Spencer J.P., Tognolini M., Borges G., Crozier A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid Redox Signal 2013, 18:1818-1892.
31. Calani L., Dall'Asta M., Derlindati E., Scazzina F., Bruni R., Del Rio D. Colonic metabolism of polyphenols from coffee, green tea, and hazelnut skins. J Clin Gastroenterol 2012, 46:S95-S99.
32. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008, 22:659-661.
33. Wang Y., Chung S.J., Song W.O., Chun O.K. Estimation of daily proanthocyanidin intake and major food sources in the U.S. diet. J Nutr 2011, 141:447-452.
34. Ovaskainen M.L., Torronen R., Koponen J.M., Sinkko H., Hellstrom J., Reinivuo H., et al. Dietary intake and major food sources of polyphenols in Finnish adults. J Nutr 2008, 138:562-566.
35. Zamora-Ros R., Andres-Lacueva C., Lamuela-Raventos R.M., Berenguer T., Jakszyn P., Barricarte A., et al. Estimation of dietary sources and flavonoid intake in a Spanish adult population (EPIC-Spain). J Am Diet Assoc 2010, 110:390-398.
36. McCullough M.L., Peterson J.J., Patel R., Jacques P.F., Shah R., Dwyer J.T. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012, 95:454-464.
37. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339:1523-1526.
38. Goldfinger T.M. Beyond the French paradox: the impact of moderate beverage alcohol and wine consumption in the prevention of cardiovascular disease. Cardiol Clin 2003, 21:449-457.